• Media type: E-Article
  • Title: Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7
  • Contributor: Lambeck, Annechien J.A.; Crijns, Anne P.G.; Leffers, Ninke; Sluiter, Wim J.; ten Hoor, Klaske A.; Braid, Mike; van der Zee, Ate G.J.; Daemen, Toos; Nijman, Hans W.; Kast, W. Martin
  • imprint: American Association for Cancer Research (AACR), 2007
  • Published in: Clinical Cancer Research
  • Language: English
  • DOI: 10.1158/1078-0432.ccr-06-1828
  • ISSN: 1557-3265; 1078-0432
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Purpose: To evaluate if serum cytokine levels could be used as diagnostic or prognostic markers in ovarian cancer.</jats:p> <jats:p>Experimental Design: A cytokine bead array was done to simultaneously analyze 14 cytokines in the sera of 187 ovarian cancer patients with complete clinicopathologic data and follow-up, 45 patients with benign ovarian tumors, and 50 healthy controls. Serum levels of the well-known serum tumor marker CA-125 were routinely measured in all patients.</jats:p> <jats:p>Results: Serum levels of CA-125, interleukin 6 (IL-6), IL-7, and IL-10 were elevated in ovarian cancer patients compared with patients with benign ovarian tumors. Analyzing the cytokines in combination with CA-125 showed that a combination of IL-7 and CA-125 serum levels could accurately predict 69% of the ovarian cancer patients, without falsely classifying patients with benign pelvic mass. The cytokines IL-6, IL-7, IL-8, IL-10, monocyte chemotactic protein-1 (MCP-1), and IP-10 and CA-125 were associated with disease-free and overall survival in univariate analysis. In multivariate analysis, IL-7 and IP-10 were independent predictors of overall survival, although after inclusion of the clininopathologic parameters, only stage and residual disease remained as independent predictors of survival.</jats:p> <jats:p>Conclusions: IL-7 levels were found to be strongly associated with ovarian cancer and could be used in combination with CA-125 to distinguish between malignant and benign ovarian tumors.</jats:p>
  • Access State: Open Access